Halozyme director to sell $3.6M in shares
HALOZYME THERAPEUTICS, INC.
Rhea-AI Filing Summary
HALOZYME THERAPEUTICS, INC. (HALO) reports that director Matthew Posard has filed a notice to sell 34,226 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC. The shares were acquired via vesting of restricted stock units between June 5, 2015 and May 5, 2022.
The notice lists an aggregate market value of $3,636,512.50 for the shares to be sold and indicates that there are 113,498,000 shares of common stock outstanding.
Positive
- None.
Negative
- None.
Key Figures
Shares to be sold: 34,226 shares
Aggregate market value of shares to be sold: $3,636,512.50
Shares outstanding: 113,498,000 shares
+2 more
5 metrics
Shares to be sold
34,226 shares
Common stock proposed to be sold by Matthew Posard under Rule 144
Aggregate market value of shares to be sold
$3,636,512.50
Value reported for the 34,226 Halozyme common shares in the notice
Shares outstanding
113,498,000 shares
Halozyme common shares outstanding as listed in the Form 144
Acquisition start date of RSU shares
June 5, 2015
Beginning of vesting period for restricted stock units that generated the shares
Acquisition end date of RSU shares
May 5, 2022
End of vesting period for restricted stock units that generated the shares
Key Terms
Rule 144, Restricted Stock Units, aggregate market value, Common
4 terms
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Restricted Stock Units financial
"The securities to be sold were acquired upon the vesting of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
aggregate market value financial
"34226 | 3636512.50 | 113498000"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.
Common financial
"Common | Morgan Stanley Smith Barney LLC Executive Financial Services"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 filing disclose for HALO?
The filing discloses that director Matthew Posard intends to sell 34,226 shares of Halozyme common stock under Rule 144, through Morgan Stanley Smith Barney LLC, from shares acquired upon vesting of restricted stock units between 2015 and 2022.
What type of securities is Matthew Posard selling in the HALO Form 144?
The Form 144 indicates that the securities are common stock of Halozyme Therapeutics, Inc., originally acquired as Restricted Stock Units granted by the issuer and later converted into shares upon vesting between 2015 and 2022.
Which broker is involved in the HALO Form 144 sale?
The filing lists Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, New York, as the broker handling the proposed sale of the 34,226 Halozyme common shares under Rule 144.
AI-generated analysis. How Rhea-AI works. Not financial advice.
